✦ LIBER ✦

Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy

✍ Scribed by Katherine M. W. Pisters; Mark G. Kris; Leslie B. Tyson; Rebecca A. Clark; Richard J. Gralla

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 443 KB
Volume: 71
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930101)71:1<226::aid-cncr2820710135>3.0.co;2-t

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose-ranging antiemetic evaluation of th

Dose-ranging antiemetic evaluation of the serotonin antagonist rg 12915 in patients receiving anticancer chemotherapy

✍ Lorraine Baltzer; Mark G. Kris; Leslie B. Tyson; James R. Rigas; Katherine M. W. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB

Background. RG 12915 is a potent, selective 5-HT3 receptor antagonist with a biologic half-life of 31-20 hours. RG 12915 prevents cisplatin-induced emesis in ferrets at doses of 0.03 mg/kg. Animal toxicology studies permitted safe testing in humans at doses of up to 2.0 mg/kg. This dose-ranging tria

Open-label comparison of the antiemetic

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy

✍ Coppes, Max J.; Lau, Robert; Ingram, Lewis C.; Wiernikowski, John T.; Grant, Ron 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Background. Nausea and vomiting are among the most unpleasant adverse side effects of cancer therapy. Procedure. An open-label dose-escalation study was conducted to assess the appropriate intravenous dose of dolasetron for pediatric patients undergoing chemotherapy. Patients received dolasetron in